Novo Nordisk announces promising data from liraglutide study  

2005.11.29
Danish healthcare company Novo Nordisk has announced promising clinical results from a phase 2b study of liraglutide, a once-daily fully-human GLP-1 analogue

Danish healthcare company Novo Nordisk has announced promising clinical results from a phase 2b study of liraglutide, a once-daily fully-human GLP-1 [glucagon-like peptide –Ed] analogue. The study included 165 patients with type 2 diabetes who previously had been treated with diet or oral antidiabetic agents.

Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk comments: "The impressive clinical data for liraglutide holds great promise for improving the treatment of type 2 diabetes, achieving glucose control and weight loss without hypoglycaemic events". Novo Nordisk expects to publish details from the study at a scientific meeting in 2006. Phase 3 studies of liraglutide including approx. 3,800 patients are planned to start in February 2006. The news was reported by financial daily newspaper Børsen.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 21,600 people in 78 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×